Background:

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex.

Applications:

WB, IHC, IF

Name of antibody:

RELA (Phospho-Ser529)

Immunogen:

Synthetic peptide of human RELA (Phospho-Ser529)

Full name:

v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Phospho-Ser529)

Synonyms:

p65; NFKB3

SwissProt:

Q04206

IHC positive control:

Human breast carcinoma

IHC Recommend dilution:

50-100

WB Predicted band size:

65 kDa

WB Positive control:

293 cells untreated or treated with TNF-α

WB Recommended dilution:

500-1000

Positive control:

Hela cells

Recommended dilution:

100-200